Optofluidics
Philadelphia, US · Delaware corporation
Find your way into Optofluidics
Founders & leadership
BC
Bernardo CordovezFounder
RW
Robert WickeNamed on SEC filing
RH
Robert HartNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$19.4M disclosed across 3 rounds · 2018–2022
▶$7MraisedDec 2022 · 11 investors · BiotechnologyRule 506(b)
▶$7MraisedDec 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rick GordonExecutive Officer, Director
- Chad SouvignierDirector
- Joseph KeeganDirector
- William SniderDirector
- Casey McGlynnExecutive Officer
- Shahram HejaziDirector
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedApr 2020 · 14 investors · BiotechnologyRule 506(b)
▶$6.7MraisedApr 2020 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William SniderDirector
- Joseph KeeganDirector
- Robert WickeExecutive Officer, Director
- Casey McGlynnExecutive Officer
- Chad SouvignierDirector
- Shahram HejaziDirector
- Offering amount
- $11.6M
- Amount sold
- $6.7M
- Proceeds to insiders
- $500K
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MraisedDec 2018 · 6 investors · Other TechnologyRule 506(b)
▶$5.6MraisedDec 2018 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Robert WickeExecutive Officer, Director
- Robert HartExecutive Officer
- Bernardo CordovezExecutive Officer
- Offering amount
- $5.6M
- Amount sold
- $5.6M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 11 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $203.8K |
| National Institute of Standards and Technology (NIST)National Institute of Standards and Technology | Phase II | 2017 | $300K |
| Food and Drug Administration (FDA)Food and Drug Administration | Phase II | 2016 | $1.5M |
| National Institute of Standards and Technology (NIST)National Institute of Standards and Technology | Phase I | 2016 | $100K |
| Food and Drug Administration (FDA)Food and Drug Administration | Phase I | 2015 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $985.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $99.8K |
| Defense Advanced Research Projects Agency (DARPA)Defense Advanced Research Projects Agency | Phase II | 2012 | $1.4M |
| National Science Foundation | Phase II | 2012 | $499.6K |
| National Science Foundation | Phase I | 2011 | $149.4K |
| Defense Advanced Research Projects Agency (DARPA)Defense Advanced Research Projects Agency | Phase I | 2011 | $99.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded Optofluidics?
- Optofluidics was founded by Bernardo Cordovez.
- How much funding has Optofluidics raised?
- Optofluidics has disclosed $19.4M raised across 3 rounds.
- Where is Optofluidics headquartered?
- Optofluidics is headquartered in Philadelphia, US.